Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-31
2006-01-31
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S553000, C552S554000, C552S557000, C552S559000
Reexamination Certificate
active
06992076
ABSTRACT:
This invention is directed to methods for providing sustained systemic concentrations of therapeutic or prophylactic agents such as GABA analogs following oral administration to animals. This invention is also directed to compounds and pharmaceutical compositions that are used in such methods.
REFERENCES:
patent: 3326758 (1967-06-01), Irmscher et al.
patent: 4024175 (1977-05-01), Satzinger
patent: 4508728 (1985-04-01), Nagai et al.
patent: 4560512 (1985-12-01), Firestone
patent: 4908353 (1990-03-01), Yamamoto et al.
patent: 5094848 (1992-03-01), Brixner
patent: 5110797 (1992-05-01), Ienaga et al.
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5541348 (1996-07-01), Araya et al.
patent: 5563175 (1996-10-01), Silverman
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 5684018 (1997-11-01), Alexander
patent: 6020370 (2000-02-01), Horwell
patent: 6028214 (2000-02-01), Silverman
patent: 6051683 (2000-04-01), Deigin et al.
patent: 6103932 (2000-08-01), Horwell
patent: 6117906 (2000-09-01), Silverman
patent: 6143738 (2000-11-01), Zasloff
patent: 0 272 462 (1998-06-01), None
patent: WO92/09560 (1992-06-01), None
patent: WO93/23383 (1993-11-01), None
patent: WO97/29101 (1997-08-01), None
patent: WO97/33858 (1997-09-01), None
patent: WO97/33859 (1997-09-01), None
patent: WO98/17627 (1998-04-01), None
patent: WO99/08671 (1999-02-01), None
patent: WO99/21824 (1999-05-01), None
patent: WO99/31057 (1999-06-01), None
patent: WO99/31074 (1999-06-01), None
patent: WO99/31075 (1999-06-01), None
patent: WO99/61424 (1999-12-01), None
patent: WO00/15611 (2000-03-01), None
patent: WO00/23067 (2000-04-01), None
patent: WO00/31020 (2000-06-01), None
patent: WO00/50027 (2000-08-01), None
Baringhaus, K.-H.; Matter, H.; Stengelin, S.; Kramer, W. Substrate specificity of the ileal and the hepatic Na+/ bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na+bile acid cotransporter.J. Lipid Res.1999, 40, pp. 2158-2168.
Batta, et al.,J. Lipid Res.,1991, 32, pp. 977-983.
Bryans, J. S.; Wustrow, D. J. 3-Substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. 1999, 19, pp. 149-177.
Bundgaard, H. inDesign of Prodrugs(Bundgaard, H. Ed.), Elsevier Science B.V., 1985, pp. 1-92.
Ho, N. F. H. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption.Ann: N. Y. Acad. Sci.1987, 507, pp. 315-329.
Jezyk, N.; Li, C.; Stewart, B. H.; Wu, X.; Bockbrader, H. N.; Fleisher, D. Transport of pregabalin in rat intestine and Caco-2 monolayers.Pharm. Res.1999, 16, pp. 519-526.
Kagedahl, M.; Swaan, P. W.; Redemann, C. T.; Tang, M.; Craik, C. S.; Szoka, F. C.; Oie, S. Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity.Pharm. Res.1997, 14, pp. 176-180.
Kim, D.C., et al., Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides,J. Drug Targeting,1993, 1, pp. 347-359.
Kramer, W.; Wess, G.; Schubert, G.; Bickel, M.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Baringhaus, K.-H.; Enhsen, A.; Glombik, H.; Mullner, S.; Neckermann, G.; Schulz, S.; Petzinger, E. Liver-specific drug targeting by coupling to bile acids.J. Biol. Chem.1992, 267, pp. 18598-18604.
Kramer, W.; Wess, G.; Neckermann, G.; Schubert, G.; Fink, J.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Baringhaus, K.-H.; Boger, G.; Enhsen, A.; Falk, E.; Friedrich, M.; Glombik, H.; Hoffmann, A.; Pittius, C.; Urmann, M. Intestinal absorption of peptides by coupling to bile acids.J. Biol. Chem.1994a, 269, pp. 10621-10627.
Kramer, W.; Wess, G.; Enhsen, A.; Bock, K.; Falk, E.; Hoffmann, A.; Neckermann, G.; Gantz, D.; Schulz, S.; Nickau, L.; Petzinger, E.; Turley, S.; Dietschy, J. M. Bile acid derived HMG-CoA reductase inhibitors.Biochim. Biophys. Acta1994b, 1227, pp. 137-154.
Kramer, W.; Stengelin, S.; Baringhaus, K.-H.; Enhsen, A.; Heuer, H.; Becker, W.; Corsiero, D.; Girbig, F.; Noll, R.; Weyland, C. Substrate specificity of the ileal and hepatic Na+bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters.J. Lipid Res.1999, 40, pp. 1604-1617.
Kullak-Ublick, G. A.; Beuers, U.; Paumgartner, G. Hepatobiliary transport.J. Hepatology2000, 32 (Suppl. 1), pp. 3-18.
Navia, M. A.; Chaturvedi, P. R. Design principles for orally bioavailable drugs.Drug Discovery Today1996, 1, pp. 179-189.
Petzinger, E.; Nichau, L.; Horz, J. A.; Schulz, S.; Wess, G.; Enhsen, A.; Falk, E.; Baringhaus, H.; K. Glombik, H.; Hoffmann, A.; Mullner, S.; Neckermann, G.; Kramer, W. Hepatobiliary transport of hepatic 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids.,Hepatology1995, 22, pp. 1801-1811.
Swaan, P. W.; Szoka, F. C.; Oie, S. Use of the intestinal and hepatic bile acid transporters for drug delivery.Adv. Drug Delivery Rev.1996, 20 pp. 59-82.
Tsjui, A.; Tamai, I. Carrier-mediated intestinal transport of drugs.Pharm. Res.1996, 13, pp. 963-977.
Cundy Kenneth C.
Gallop Mark A.
Zhou Cindy X.
Badio Barbara P.
XenoPort, Inc.
LandOfFree
Bile-acid derived compounds for providing sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid derived compounds for providing sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid derived compounds for providing sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3577265